Vipalanebart

韦帕奈拜单抗

Report date: 2024/01/04 14:48:46

Base Information

Drug NameVipalanebart
Drug Alias NameLY-3451838
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionPituitary adenylate cyclase-activating polypeptide type I receptor antagonists
TargetsPituitary adenylate cyclase-activating polypeptide type I receptor
Therapy Area/IndicationsMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingapore
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsMigraine Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A